Théa and Pierre Fabre announce their technological partnership.
Théa and Pierre Fabre announce their technological partnership for the sterile packaging of Blephaderm®, Théa's new ophthalmic care product.
Clermont-Ferrand and Castres (France), May 3, 2024 – French pharmaceutical laboratories Théa and Pierre Fabre, renowned respectively for their expertise in ophthalmology and dermatology, are joining forces on the occasion of the launch of Blephaderm®, Théa's latest product in eyelid care.
Resulting from Théa's research and development efforts, Blephaderm® stands out with its exclusive formulation, offering a combination of three main natural active ingredients selected for their efficacy and tolerance. To ensure the optimal packaging of the latest addition to the product range dedicated to eyelid hygiene and care, Théa has chosen the DEFI system.
The combination of a unique sterilization process and the DEFI system (Exclusive Intact Formula Device), developed and patented by Laboratoires Pierre Fabre, ensures the perfect sterility of the preservative-free formula throughout its use. This partnership, bringing together two French pharmaceutical companies, demonstrates Théa and Laboratoires Pierre Fabre’s commitment to ensuring the quality, reliability, and safety of their healthcare products for patients.
"Pierre Fabre revolutionized the dermo-cosmetic universe by inventing Sterile Cosmetics, a unique, unparalleled technological process that has never been surpassed by any of its competitors. Global brands within its dermo-cosmetic division, such as Eau Thermale Avène, Ducray, and A-Derma, benefit from it. We were delighted to see Théa, a French company and a global leader in ophthalmology, recognize the potential of this unique technology, leading to this collaboration. Indeed, this manufacturing process is perfectly suited for skincare products intended for the delicate area of the eyelids and eye contour. This collaboration is a wonderful alliance of projects between French companies, to the benefit of patients," stated Eric Ducournau, CEO of Laboratoires Pierre Fabre.
"We are proud to launch a product developed and manufactured in France, both in France and internationally. Théa shares the values of Pierre Fabre Laboratories and their commitment to continue promoting French innovation in service of healthcare professionals and patients worldwide," added Jean-Frédéric Chibret, President of the Théa Group.
About BLEPHADERM®
As a pioneer and leader in preservative-free eye treatments, Théa's research and development teams have contributed to the formulation of Blephaderm® with three main natural ingredients: hyaluronic acid, trehalose, and extracts of Ophiopogon japonicus roots. Blephaderm® is an eyelid and eye contour cream designed for sensitive, irritated, dry, and atopic-prone skin.
Preservative-free, fragrance-free, and alcohol-free, this newcomer to the product range dedicated to eyelid hygiene and care has been developed and tested under dermatological and ophthalmological control.
The BLEPHADERM® formula benefits from Sterile Cosmetics™ technology, which enables the creation of a sterile and preservative-free cream.
Sterile Cosmetics™ innovation combines:
Rigorous and limited selection of essential ingredients to offer safe and effective formulas.
A unique process in dermo-cosmetics: sterilization throughout the manufacturing process (with complete sterilization of production equipment, a patented formula sterilization method, and packaging in a sterile environment).
An innovative sealing system: the D.E.F.I (Device for Exclusive Formula Integrity) system is a revolutionary approach in dermo-cosmetic packaging design, developed and patented by Pierre Fabre. This perfectly airtight system helps preserve a completely sterile formula, preventing bacteria and other germs from contaminating the formula throughout the product's use.
About Théa
Théa is the leading independent European pharmaceutical laboratory specializing in research, development, and commercialization of ophthalmic products.
Based in Clermont-Ferrand, France, this family-owned company has nearly 2000 employees and has expanded by opening over 35 subsidiaries and offices across Europe, North Africa, North and South America, and the Middle East. Its products are manufactured 100% in Europe, with 60% in France, and are available in 75 countries worldwide. In 2023, Théa's revenue reached 923 million euros. For more information, please visit www.laboratoires-thea.com, Laboratoires Théa: mon entreprise | LinkedIn
About Laboratoires Pierre Fabre
Laboratoires Pierre Fabre rank as the 2nd global company in dermo-cosmetics and are among the leading pharmaceutical laboratories in Europe. Their portfolio consists of several international brands and medical franchises, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Pierre Fabre Pharma Care, Eau Thermale Avène, Ducray, A-Derma, Klorane, René Furterer, Darrow, Même Cosmetics, Naturactive, Elgydium, Inava, and Arthrodont.
In 2023, Laboratoires Pierre Fabre achieved a turnover of 2.83 billion euros, with 70% from international markets spanning 120 countries. Established in the Occitanie region, they manufacture 95% of their products in France and employ over 10,000 collaborators worldwide. Their annual R&D budget amounts to nearly 200 million euros, with approximately 50% dedicated to targeted therapies in oncology and 40% to skin therapies and care.
The ultra-majority shareholder (86%) of Laboratoires Pierre Fabre is a Foundation bearing the same name, recognized as a public utility. This capital structure ensures the independence of the company and its long-term vision. Dividends paid to the Pierre Fabre Foundation enable it to develop and finance humanitarian health access programs in Southern countries. Through an international employee share ownership plan, employees are the other shareholders of the company.
Laboratoires Pierre Fabre’s CSR (Corporate Social Responsibility) approach is assessed by AFNOR Certification at the "Exemplary" level of the RSE Committed label (ISO 26,000 standard for sustainable development).
For further information, visit www.pierre-fabre.com, Pierre Fabre Group : Présentation | LinkedIn